DURHAM, N.C., September 13, 2017 — Premier Research's head of patient engagement will address patients' emerging role in the development of novel drugs at the Global Genes RARE Patient Advocacy Summit in Irvine, California.
Juliet Moritz, the CRO's Executive Director for Patient Engagement and Strategic Development, will join Alvin Shih, CEO of the biotech company Enzyvant, at 10:30 a.m. Thursday, September 14, to present The R&D Roadmap and the Growing Role of Patients.
Rare disease patients, active partners in pharmaceutical R&D for years, have become foundational within research labs, clinical trials, and the regulatory process. Ms. Moritz and Dr. Shih will discuss approval pathways for new rare disease therapies and the many ways patients are influencing the process.